NCT05329298 - A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2023

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

BPI-361175

Subjects will receive BPI-361175 until disease progression

Trial Locations (8)

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

RECRUITING

Jiangsu Cancer Hospital, Nanjing

RECRUITING

Jiangsu Province Hospital, Nanjing

RECRUITING

the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

RECRUITING

Xiangya Hospital of Central South University, Changsha

RECRUITING

Hunan cancer hospital, Changsha

RECRUITING

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

RECRUITING

Henan Cancer Hospital, Zhengzhou